Chronic Hepatitis b, Liver Fibrosis
Conditions
Keywords
hepatitis b, fibrosis, regucalcin, liver
Brief summary
This study, it was aimed to investigate the relationship between serum regucalcin level and liver fibrosis level in patients with CHB infection.
Detailed description
Chronic hepatitis B (CHB) infection continues to be an important health problem due to its high morbidity and mortality. For this reason, it is very important to determine the appropriate timing to start antiviral therapy in patients with CHB infection and to evaluate the stage of liver fibrosis in the treatment follow-up. Liver biopsy is the gold standard for detecting liver fibrosis. Although it is generally accepted to be a safe procedure, it can cause some serious complications. For this reason, in recent years, many studies have been conducted on new noninvasive tests in the evaluation of liver fibrosis. One of them is the serum regucalcin level. Studies have shown that serum regucalcin levels increase in liver damage, but there is no study in the literature comparing liver fibrosis and serum regucalcin levels in CHB infection. This study, it was aimed to investigate the relationship between serum regucalcin level and liver fibrosis level in patients with CHB infection.
Interventions
DIAGNOSTIC_TESTSerum regucalcin level
During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
Sponsors
Konya Meram State Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Patients undergoing liver biopsy for chronic hepatitis b
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Being followed up with a diagnosis of chronic hepatitis B * Not having a known history of liver disease who applied to our outpatient clinic for other reasons * Having a liver biopsy * ≥18 years
Exclusion criteria
* \<18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of serum regucalcin levels with liver fibrosis levels | Performing liver biopsies: 3 months, data collection: 1 month, writing the article: 1 month | We grouped chronic hepatitis b patients as mild fibrosis (stage 1-2) and moderate fibrosis (stage 3-4) according to the fibrosis stage at liver biopsy stage. We selected healthy volunteers without liver disease as the control group. We will measure the serum regucalcin level in these 3 groups and make a comparison between the groups. We want to show the relationship between serum regucalcin level and fibrosis level in chronic hepatitis b. |
Countries
Turkey (Türkiye)
Outcome results
None listed